Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6289920 | 0.83 | TRPV1 (0.49) | EPHX2ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6289473 | 0.76 | MMP2 (0.39) | CYP3A4 | |
| SCHEMBL6289463 | 0.69 | ACHE (0.43) | ALDH1A1ALOX15 | |
| SCHEMBL16785550 | 0.67 | CYP3A4 (0.60) | EPHX2ALDH1A1CYP3A4HPGDTRPV1 | |
| SCHEMBL8393845 | 0.67 | TRPV1 (0.50) | EPHX2ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17335527 | 0.66 | EPHX2 (0.61) | EPHX2ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL15678793 | 0.66 | LMNA (0.76) | ALDH1A1CYP3A4HPGD | |
| SCHEMBL21998933 | 0.66 | HTT (0.71) | EPHX2ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17335642 | 0.66 | EPHX2 (0.79) | EPHX2ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1949206 | 0.66 | CA1 (0.51) | EPHX2CYP3A4TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6870065-B2 | Bifunctional boronic compound complexing reagents and complexes | CAMBREX BIO SCIENCE ROCKLAND, INC. (US) | 2005-03-22 | — | — | US | disclosed |
| US-20030105280-A1 | Bifunctional boronic compound complexing reagents and complexes | AHLEM CLARENCE N (US) | 2003-06-05 | — | — | US | disclosed |
| US-6414122-B1 | BIOCHEMICAL CONJUGATION TO PROTEINS, PEPTIDES, HORMONES, POLYSACCHARIDES, NUCLEIC ACIDS, LIPOSOMES, RADIONUCLIDES, HAPTENS, AND TOXINS | PROLINX, INC. | 2002-07-02 | — | — | US | disclosed |
| US-6156884-A | Bifunctional boronic compound complexing reagents and complexes | PROLINX, INC. (US) | 2000-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105280-A1 | Bifunctional boronic compound complexing reagents and complexes | CHN2, CFH, COG2 | EPHX2 292/4885ALDH1A1 3191/4885CYP1A2 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.